Maze Therapeutics Ratios (2024-2025) | MAZE

Ratios Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Profitability
EBT Margin (Quarter) 938.55%-1,001.24%
EBIT Margin (Quarter) 930.37%-969.16%
EBITDA Margin (Quarter) 930.37%-969.16%
Operating Margin (Quarter) 930.37%-969.16%
Net Margin (Quarter) 92.56%-990.08%
FCF Margin (Quarter) 964.37%-918.96%
Efficiency
Assets Average (Quarter) 286.69M318.18M362.79M409.59M
Equity Average (Quarter) -333.01M-273.45M-297.86M-9.56M277.15M320.84M367.20M
Invested Capital (Quarter) -403.66M-262.37M-284.53M-311.18M292.07M262.24M379.44M354.97M
Asset Utilization Ratio (Quarter) 0.060.01
Leverage & Solvency
Equity Ratio (Quarter) -1.290.880.860.900.89
Valuation
Enterprise Value (Quarter) -30.02M-175.06M-149.61M-196.81M-294.40M-264.50M-383.94M-341.92M
Return Ratios
Return on Sales (Quarter) 9.27%-9.90%3.26%2.97%-48.32%
Return on Capital Employed (Quarter) 0.19%-0.42%-0.39%-0.37%
Return on Invested Capital (Quarter) -0.46%-0.42%-0.39%
Return on Assets (Quarter) 0.18%-0.38%-0.35%-0.32%
Return on Equity (Quarter) -0.19%-5.43%-0.44%-0.39%-0.36%